However, when selective PPARγ agonist rosiglitazone (RSG) was used for treating diabetes, it had adverse cardiovascular effects, such as stimulating cardiac hypertrophy and oxidative stress that are independent of cardiomyocyte PPARγ. The gene discussed is PPARG; the disease is cardiac hypertrophy.